| Source: |
| Type: |
| Vimentin, a major constituent of the intermediate filament family of proteins, is ubiquitously expressed in normal mesenchymal cells and is known to maintain cellular integrity and provide resistance against stress. Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure. In many epithelial-derived tumors (carcinomas), elevated Vimentin expression is often observed in cancer cells that have undergone EMT. This upregulation is characteristic of a shift toward a mesenchymal state, which is associated with reduced cell–cell adhesion and increased motility. Vimentin expression is also noted in the tumor stroma, reflecting the presence and activation of mesenchymal cells such as cancer-associated fibroblasts (CAFs). This dual expression can contribute to the remodeling of the tumor microenvironment. The degree of Vimentin expression may vary depending on the tumor type, grade, and stage. More aggressive and advanced tumors tend to show higher levels of Vimentin expression. High Vimentin expression has been correlated with poor clinical outcomes in several cancers, including breast, colorectal, prostate, and lung cancers. Elevated Vimentin levels are typically associated with higher tumor grade, increased invasiveness, enhanced metastatic potential, and a greater risk of recurrence. As a component of the EMT signature, high Vimentin expression can serve as an indicator of a more aggressive tumor phenotype and is often associated with reduced overall survival. - vimentin up-regulation is often used as a marker of EMT in cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 4699- | PTS, | Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vivo, | BC, | MDA-MB-231 |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 65- | QC, | Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB |
| - | in-vitro, | BC, | NA |
| 54- | QC, | Quercetin‑3‑methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways |
| - | in-vitro, | BC, | MCF-7 |
| 53- | QC, | Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | NA, | NA, | MDA-MB-468 |
| 95- | QC, | Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent |
| - | in-vitro, | Pca, | PC3 |
| 80- | QC, | Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway |
| - | in-vitro, | Pca, | PC3 |
| - | in-vitro, | Pca, | CD44+ | - | in-vitro, | NA, | CD133+ | - | in-vitro, | NA, | PC3 | - | in-vitro, | NA, | LNCaP |
| 923- | QC, | Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health |
| - | Review, | Var, | NA |
| 3368- | QC, | The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update |
| - | Review, | Var, | NA |
| 2687- | RES, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | NA, | NA | - | Review, | AD, | NA |
| 3076- | RES, | Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells |
| - | Review, | Var, | NA |
| 3092- | RES, | Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action |
| - | Review, | BC, | MDA-MB-231 | - | Review, | BC, | MCF-7 |
| 1047- | RES, | Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 878- | RES, | Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression |
| - | vitro+vivo, | CRC, | LoVo |
| 1748- | RosA, | The Role of Rosmarinic Acid in Cancer Prevention and Therapy: Mechanisms of Antioxidant and Anticancer Activity |
| - | Review, | Var, | NA |
| 1745- | RosA, | Rosmarinic acid and its derivatives: Current insights on anticancer potential and other biomedical applications |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 3027- | RosA, | Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway |
| - | in-vitro, | HCC, | SMMC-7721 cell |
| 3037- | RosA, | Unraveling rosmarinic acid anticancer mechanisms in oral cancer malignant transformation |
| - | in-vitro, | Oral, | SCC9 | - | in-vitro, | Oral, | HSC3 |
| 1132- | RT, | Rutin Promotes Proliferation and Orchestrates Epithelial–Mesenchymal Transition and Angiogenesis in MCF-7 and MDA-MB-231 Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 5127- | Sal, | Salinomycin repressed the epithelial–mesenchymal transition of epithelial ovarian cancer cells via downregulating Wnt/β-catenin pathway |
| - | in-vitro, | Ovarian, | NA |
| 1135- | Selenate, | Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation |
| - | in-vitro, | CRC, | DLD1 |
| 1726- | SFN, | Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential |
| - | Review, | Var, | NA |
| 3301- | SIL, | Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid |
| - | Review, | Var, | NA |
| 3296- | SIL, | Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway |
| - | in-vitro, | Oral, | Ca9-22 | - | in-vivo, | Oral, | YD10B |
| 3282- | SIL, | Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions |
| - | Review, | NA, | NA |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Nor, | MCF12A | - | in-vivo, | NA, | NA |
| 1137- | Taur, | Taurine Attenuates Epithelial-Mesenchymal Transition-Related Genes in Human Prostate Cancer Cells |
| - | in-vitro, | Pca, | NA |
| 1138- | TQ, | Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 3427- | TQ, | Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets |
| 3422- | TQ, | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
| - | Review, | Var, | NA |
| 1139- | UA, | Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells |
| - | in-vitro, | Lung, | A549 |
| 5022- | UA, | Ursolic Acid’s Alluring Journey: One Triterpenoid vs. Cancer Hallmarks |
| - | Review, | Var, | NA |
| 4856- | Uro, | Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro |
| - | in-vitro, | NPC, | CNE1 | - | in-vitro, | NPC, | CNE2 |
| 4838- | Uro, | The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention |
| - | Review, | Var, | NA |
| 4844- | Uro, | Urolithin A Inhibits Epithelial–Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 1217- | VitC, | High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition |
| - | in-vitro, | BC, | Bcap37 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 1740- | VitD3, | Vitamin D and Cancer: An Historical Overview of the Epidemiology and Mechanisms |
| - | Review, | Var, | NA |
| 2366- | VitD3, | Vitamin D3 decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| - | in-vitro, | Oral, | NA | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | HaCaT |
| 1820- | VitK3, | Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
| 4888- | ZER, | 5-FU, | Modulation of the tumor microenvironment by zerumbone and 5-fluorouracil in colorectal cancer by target in cancer-associated fibroblasts |
| - | in-vitro, | CRC, | CT26 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:336 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid